Literature DB >> 11133384

The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission.

K S MacDonald1, J E Embree, N J Nagelkerke, J Castillo, S Ramhadin, S Njenga, J Oyug, J Ndinya-Achola, B H Barber, J J Bwayo, F A Plummer.   

Abstract

Certain HLAs may, in part, account for differences in human immunodeficiency virus type 1 (HIV-1) susceptibility by presenting conserved immunogenic epitopes for T cell recognition. The HLA supertype A2/6802 is associated with decreased susceptibility to HIV-1 among sex workers. The alleles in this supertype present the same HIV-1 peptide epitopes for T cell recognition in some cases. This study sought to determine whether the HLA A2/6802 supertype influenced HIV-1 transmission in a prospective cohort of HIV-1-infected mothers and children in Kenya. Decreased perinatal HIV-1 infection risk was strongly associated with possession of a functional cluster of related HLA alleles, called the A2/6802 supertype (odds ratio, 0.12; 95% confidence interval, 0.03-0.54; P=.006). This effect was independent of the protective effect of maternal-child HLA discordance. These data provide further evidence that HLA supertypes are associated with differential susceptibility to HIV-1 transmission.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11133384     DOI: 10.1086/318092

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

2.  Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals.

Authors:  Janet M Young; Jim A Turpin; Runa Musib; Opendra K Sharma
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-15       Impact factor: 2.205

Review 3.  Resistance to HIV infection.

Authors:  M Marmor; K Hertzmark; S M Thomas; P N Halkitis; M Vogler
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

4.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque.

Authors:  Natalia Kovalova; Michael D Knierman; Patricia L Brown-Augsburger; Victor J Wroblewski; Lukasz K Chlewicki
Journal:  Immunogenetics       Date:  2019-11-27       Impact factor: 2.846

6.  Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS.

Authors:  Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

7.  A sequence-based approach demonstrates that balancing selection in classical human leukocyte antigen (HLA) loci is asymmetric.

Authors:  Paola G Bronson; Steven J Mack; Henry A Erlich; Montgomery Slatkin
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

8.  How fast could HIV change gene frequencies in the human population?

Authors:  Deborah Cromer; Steven M Wolinsky; Angela R McLean
Journal:  Proc Biol Sci       Date:  2010-03-10       Impact factor: 5.349

9.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers.

Authors:  W Jennes; D Evertse; M-Y Borget; B Vuylsteke; C Maurice; J N Nkengasong; L Kestens
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.